Diagnostic and prognostic impact of desmocollins in human lung cancer

Journal of Clinical Pathology

Volumn 65, Issue 12, 2012, Pages 1100-1106

  Cui, Tiantian ^a   Chen, Yuan ^a   Yang, Linlin ^a   Mireskandari, Masoud ^a   Knösel, Thomas ^b   Zhang, Qing ^a   Kohler, Lukas Herbert ^a   Kunze, Almut ^c   Presselt, Norbert ^c   Petersen, Iver ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Central Clinic Bad Berka   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDINE; DESMOCOLLIN; DESMOCOLLIN 1; DESMOCOLLIN 2; DESMOCOLLIN 3; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; EXON; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

ADULT; CARCINOMA; CELL LINE, TUMOR; DESMOCOLLINS; DOWN-REGULATION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 84870058184     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200630     Document Type: Article

References (34)

1. Holthöfer B, Windoffer R, Troyanovsky S, et al. Structure and function of desmosomes. Int Rev Cytol 2007;264:65-163. (Pubitemid 47625262)
2. Chidgey M, Dawson C. Desmosomes: a role in cancer? Br J Cancer 2007;96:1783-7. (Pubitemid 46912021)
3. 2+-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. J Cell Biol 1997;138:193-201.
4. Marcozzi C, Burdett ID, Buxton RS, et al. Coexpression of both types of desmosomal cadherin and plakoglobin confers strong intercellular adhesion. J Cell Sci 1998;111:495-509. (Pubitemid 28098398)
5. Tselepis C, Chidgey M, North A, et al. Desmosomal adhesion inhibits invasive behavior. Proc Natl Acad Sci USA 1998;95:8064-9. (Pubitemid 28326066)
6. Chun MG, Hanahan D. Genetic deletion of the desmosomal component desmoplakin promotes tumour microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis. PLoS Genet 2010;6:e1001120.
7. Kolegraff K, Nava P, Helms MN, et al. Loss of desmocollin-2 confers a tumourigenic phenotype to colonic epithelial cells through activation of Akt/β-catenin signaling. Mol Biol Cell 2011;22:1121-34.
8. Kurzen H, Münzing I, Hartschuh W. Expression of desmosomal proteins in squamous cell carcinomas of the skin. J Cutan Pathol 2003;30:621-30. (Pubitemid 37372350)
9. Chen YJ, Chang JT, Lee L, et al. DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene 2007;26:467-76. (Pubitemid 46122837)
10. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489-500. (Pubitemid 38610250)
11. Fukuoka J, Dracheva T, Shih JH, et al. Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol 2007;8:276-83. (Pubitemid 46096551)
12. Chen J, O'Shea C, Fitzpatrick JE, et al. Loss of desmocollin 3 in skin tumour development and progression. Mol Carcinog 2012;51:535-45.
13. Cui T, Chen Y, Yang L, et al. DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. Br J Cancer 2011;104:1013-19.
14. Oshiro MM, Kim CJ, Wozniak RJ, et al. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res 2005;7:669-80.
15. Difilippantonio S, Chen Y, Pietas A, et al. Gene expression profiles in human non-small and small-cell lung cancers. Eur J Cancer 2003;39:1936-47. (Pubitemid 37311192)
16. Sobin LH, Gospodarowicz MK, Wittekind CH. TNM Classification of Malignant tumours. 2010;138-47.
17. Chen Y, Knösel T, Kristiansen G, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 2003;200:640-6. (Pubitemid 36987314)
18. Getsios S, Huen AC, Green KJ. Working out the strength and flexibility of desmosomes. Nat Rev Mol Cell Biol 2004;5:271-81. (Pubitemid 38480608)
19. Alazawi WO, Morris LS, Stanley MA, et al. Altered expression of desmosomal components in high-grade squamous intraepithelial lesions of the cervix. Virchows Arch 2003;443:51-6. (Pubitemid 36920951)
20. Breuninger S, Reidenbach S, Sauer CG, et al. Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumour progression. Am J Pathol 2010;176:2509-19.
21. Papagerakis S, Shabana AH, Pollock BH, et al. Altered desmoplakin expression at transcriptional and protein levels provides prognostic information in human oropharyngeal cancer. Hum Pathol 2009;40:1320-9.
22. Yashiro M, Nishioka N, Hirakawa K. Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer 2006;42:2397-403. (Pubitemid 44307618)
23. Nei H, Saito T, Tobioka H, et al. Expression of component desmosomal proteins in uterine endometrial carcinoma and their relation to cellular differentiation. Cancer 1996;78:461-70. (Pubitemid 26250532)
24. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 2009;22:709-17.
25. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J Thorac Oncol 2011;6:1190-9.
26. Renouf DJ, Wood-Baker R, Ionescu DN, et al. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol 2009;4:486-91.
27. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3:1468-81.
28. Carney DN. Lung cancer-time to move on from chemotherapy. N Engl J Med 2000;346:126-8.
29. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801. (Pubitemid 29269249)
30. Boelens MC, van den Berg A, Vogelzang I, et al. Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. J Clin Pathol 2007;60:608-14. (Pubitemid 46975213)
31. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-39. (Pubitemid 34535443)
32. Kargi A, Gurel D, Tuna B. The diagnostic value of ttf-1, ck 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007;15:415-20. (Pubitemid 350307847)
33. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and egfr status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, ttf-1, cytokeratin 5/6, and p63, and egfr mutation analysis. J Thorac Oncol 2010;5:436-41.
34. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumour samples. Am J Surg Pathol 2010;34:1805-11.